carolina.gif (1377 bytes)

NEWS SERVICES
210 Pittsboro Street, Campus Box 6210
Chapel Hill, NC  27599-6210
(919) 962-2091   FAX: (919) 962-2279
 www.unc.edu/news/

 ADVISORY

Not for publication

Nov. 15, 2000 -- No. 612

Colloquium to cover rapidly evolving research on hemophilia, end with announcement of professorship

 

3:30 p.m. Thursday (Nov. 16)

UNC Lineberger Comprehensive Cancer Center Plaza Conference Room

 

Internationally renowned scientists from the University of North Carolina at Chapel Hill, M.D. Anderson Hospital and Novo Nordisk Pharmaceuticals Inc. will talk about the rapidly evolving research on treatment for hemophilia – and the hope such research offers for patients who have this disease.

Open to the public, the free hour-long colloquium, titled "Factor VII and the Regulation of Coagulation," will feature the following talks:

• Dr. Ulla Hedner of Novo Nordisk Pharmaceuticals will speak on "Factor VII Structure, Function and Properties."

• Dr. Keith Hoots of M.D. Anderson Hospital will discuss "The Clinical Use of Recombinant Factor VIIa."

• Dr. Gilbert White of UNC-CH will address "The Future of Hemophilia Care."

The colloquium will conclude with an announcement of the Harold R. Roberts Professorship, in honor of the Sarah Graham Kenan professor of medicine and pathology in the UNC-CH School of Medicine. Roberts is the founding director of the university’s Center for Thrombosis and Hemostasis.

The UNC-CH Comprehensive Hemophilia Diagnostic and Treatment Center, a unit of the thrombosis center, is the second largest treatment site of its kind in the United States and provides care for about 600 patients with hemophilia, von Willebrand disease and other bleeding disorders. It has been a resource for clinical trials of new therapies – it was one of three U.S. sites to begin trials of recombinant factor IX in February 1995.

Hemophilia devastates the lives of more than 15,000 Americans. The hereditary disease strikes predominantly males. Hemophilia results when a blood protein crucial for clotting is missing, defective or weak. Treatment usually consists of replacing the missing clotting protein (called a factor) either with a substitute obtained from human plasma or, more recently, with genetically engineered preparations.

- 30 -

 

Center for Thrombosis and Hemostasis contact: Margo Price, (919) 966-6011

UNC-CH News Services contact: Deb Saine, (919) 962-8415